Dr. Steve Felstead, MB-ChB, is Chief Medical Officer at Juvenescence. He is also Managing Director of Deljay Consulting Limited, providing services to Pharma, Biotech, and Venture Capital industries.

Dr. Felstead was Vice President, Head of Clinical Research in the pharmatherapeutics division at Pfizer Inc., in both the UK and the US. Steve was responsible for clinical development and pharmacology, translational and molecular medicine, preclinical and clinical statistics. He led the team that laid the groundwork for the NIH/NCATS program for systematic evaluation of drug repurposing. In addition to his line management and senior leadership roles, Dr. Felstead was involved in multiple projects, as member and team leader, helping to develop Zithromax (azithromycin), Viagra (sildenafil), and Vfend (voriconazole). Dr. Felstead led the Viagra (sildenafil) team when the first pulmonary hypertension study was being designed, which led to the successful Revatio development program. He also led the Celsentri/Selzentry (maraviroc) team through to successful transatlantic registration of this novel anti-retroviral medicine.